LBD Diagnosis Challenges

75% of LBD patients are initially given a wrong diagnosis.

A man performing Alzheimer's disease research

SYNTap Test Capabilities

This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.

Specification Sheet

SYNTap Spec Sheet - Disease Lead

“According to the Lewy Body Dementia Association (LBDA), its takes an average of three doctors and more than 18 months to correctly diagnose LBD. Most doctors fail to recognize the signs of LBD; the symptoms are very similar to Alzheimer’s disease and other neurodegenerative disorders, such as Parkinson’s disease” (Ref.3)

Accurate Early Diagnosis Aids Proper Disease Management

Identifying LBD/DLB earlier in the disease can aid in making therapeutic decisions

SYNTap Biomarker Test provides clinicians with valuable information to make an early diagnosis, helping to avoid medications, which can bring on severe side effects in LBD/DLB patients.

“Many commonly used medications can produce severe side effects in patients with DLB, notably medications with anticholinergic or antidopaminergic actions. Substantial improvement in quality of life can be achieved by ceasing these treatments.”  (Ref.7)

“Common difficulties in establishing diagnosis included atypical or non-specific presentations, conditions with very low prevalence, the presence of co-morbid illnesses and perceptual features, which are all characteristic of LBD.”  (Ref.3)

Download the SYNTap Test Specification Sheet for details.